Reschke R - Search Results

1

Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines.

Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF. Reschke R, et al. Cancer Immunol Res. 2022 Oct 4;10(10):1167-1174. doi: 10.1158/2326-6066.CIR-22-0362. Cancer Immunol Res. 2022. PMID: 35977003 Free PMC article.

2

Gummatous Cutaneous Syphilis.

Reschke R, Kunz M, Ziemer M. Reschke R, et al. Dtsch Arztebl Int. 2022 Jul 1;119(26):457. doi: 10.3238/arztebl.m2022.0050. Dtsch Arztebl Int. 2022. PMID: 36321683 Free PMC article. No abstract available.

3

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.

Reschke R, Yu J, Flood B, Higgs EF, Hatogai K, Gajewski TF. Reschke R, et al. J Immunother Cancer. 2021 Sep;9(9):e003521. doi: 10.1136/jitc-2021-003521. J Immunother Cancer. 2021. PMID: 34593622 Free PMC article.

4

Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction.

Rouhani SJ, Trujillo JA, Pyzer AR, Yu J, Fessler J, Cabanov A, Higgs EF, Cron KR, Zha Y, Lu Y, Bloodworth JC, Abasiyanik MF, Okrah S, Flood BA, Hatogai K, Leung MY, Pezeshk A, Kozloff L, Reschke R, Strohbehn GW, Chervin CS, Kumar M, Schrantz S, Madariaga ML, Beavis KG, Yeo KJ, Sweis RF, Segal J, Tay S, Izumchenko E, Mueller J, Chen LS, Gajewski TF. Rouhani SJ, et al. Among authors: reschke r. Res Sq [Preprint]. 2021 Nov 24:rs.3.rs-1083825. doi: 10.21203/rs.3.rs-1083825/v1. Res Sq. 2021. PMID: 34845442 Free PMC article. Preprint.

5

Leveraging STING, Batf3 Dendritic Cells, CXCR3 Ligands, and Other Components Related to Innate Immunity to Induce A "Hot" Tumor Microenvironment That Is Responsive to Immunotherapy.

Reschke R, Olson DJ. Reschke R, et al. Cancers (Basel). 2022 May 16;14(10):2458. doi: 10.3390/cancers14102458. Cancers (Basel). 2022. PMID: 35626062 Free PMC article. Review.

6

CXCL9 and CXCL10 bring the heat to tumors.

Reschke R, Gajewski TF. Reschke R, et al. Sci Immunol. 2022 Jul 22;7(73):eabq6509. doi: 10.1126/sciimmunol.abq6509. Epub 2022 Jul 22. Sci Immunol. 2022. PMID: 35867802 Review.

7

Correction: Reschke, R.; Olson, D.J. Leveraging STING, Batf3 Dendritic Cells, CXCR3 Ligands, and Other Components Related to Innate Immunity to Induce a "Hot" Tumor Microenvironment That Is Responsive to Immunotherapy. Cancers 2022, 14, 2458.

Reschke R, Olson DJ. Reschke R, et al. Cancers (Basel). 2024 Mar 21;16(6):1234. doi: 10.3390/cancers16061234. Cancers (Basel). 2024. PMID: 38539578 Free PMC article.

8

Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.

Reschke R, Gussek P, Boldt A, Sack U, Köhl U, Lordick F, Gora T, Kreuz M, Reiche K, Simon JC, Ziemer M, Kunz M. Reschke R, et al. Int J Mol Sci. 2021 Jul 27;22(15):8017. doi: 10.3390/ijms22158017. Int J Mol Sci. 2021. PMID: 34360781 Free PMC article. Clinical Trial.

9

Recurrent Bullous Eruption in a Young Woman.

Reschke R, Dumann K, Ziemer M. Reschke R, et al. JAMA Dermatol. 2019 Mar 1;155(3):373-374. doi: 10.1001/jamadermatol.2018.4006. JAMA Dermatol. 2019. PMID: 30540341 No abstract available.

10

Rechallenge of targeted therapy in metastatic melanoma.

Reschke R, Simon JC, Ziemer M. Reschke R, et al. J Dtsch Dermatol Ges. 2019 May;17(5):483-486. doi: 10.1111/ddg.13766. Epub 2019 Feb 13. J Dtsch Dermatol Ges. 2019. PMID: 30758138 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters